|  |  |  |
| --- | --- | --- |
| 09-82918_logo_E_RGB | **International Narcotics Control Board** | **FORM B** |

**ANNUAL ESTIMATES OF REQUIREMENTS FOR NARCOTIC DRUGS, MANUFACTURE   
OF SYNTHETIC DRUGS, AND CULTIVATION OF THE OPIUM POPPY, THE CANNABIS PLANT AND THE COCA BUSH**

**Single Convention on Narcotic Drugs of 1961: articles 1, 12 and 19.**

**1972 Protocol amending the Single Convention on Narcotic Drugs of 1961: articles 5 and 9.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Country or territory:** |  | | **Date:** |  |
| **Competent office:** |  | | | |
| **Responsible officer’s name:** |  | | **Signature:** |  |
| **Title or function:** |  | | | |
| **Telephone number(s):** |  | | **E-mail:** |  |
| **The estimates relate to the calendar year:** | |  |  | |

**Remarks**

|  |
| --- |
|  |

The present form should be completed and reach the Board not later than 30 June of the year preceding the year to which the estimates relate. The form can be downloaded from the INCB website. Once completed, the form should be sent in a single copy to:

International Narcotics Control Board

**Vienna International Centre**

**P.O. Box 500   
1400 Vienna  
Austria**

**Telephone: (+43-1) 26060-4277**

**E-mail: incb.secretariat@un.org, incb.narcotics@un.org Website: http://www.incb.org/**

Please also consider submitting this form in XML format by e-mail

**INSTRUCTIONS**

***General***:

1. This form is divided into seven parts:

Part I: Background information and statement of the method;

Part II: Annual estimates of requirements for narcotic drugs;

Part III: Annual estimates for the manufacture of synthetic drugs;

Part IV: Annual estimates of the cultivation of the opium poppy for opium production;

Part V: Annual estimates of the cultivation of the opium poppy for purposes other than opium production;

Part VI: Annual estimates of the cultivation of the cannabis plant for cannabis production;

Part VII: Annual estimates of the cultivation of the coca bush for coca leaf production.

2. In order to ensure the accurate completion of this form, the definitions given below, in accordance with the provisions of article 1 of the Single Convention on Narcotic Drugs of 1961, should be borne in mind:

*(a)* “Consumption” means the act of supplying a narcotic drug to any person or enterprise for retail distribution, medical use or scientific research;

*(b)* “Drug” means any of the substances included in Schedules I or II of the 1961 Convention, whether natural or synthetic, and thus subject to specific control measures under the Convention;

*(c)* “Manufacture” means all processes, other than production (see the definition below), by which drugs may be obtained, and includes refining and the transformation of drugs into other drugs;

*(d)* “Preparation” means any mixture, solid or liquid, subject to international control owing to the fact that it contains a drug under international control. Preparations listed in Schedule III of the 1961 Convention are exempted from some control measures;

*(e)* “Production” means the separation of opium, coca leaves, cannabis and cannabis resin from the plants from which they are obtained;

*(f)* “Stocks” means the amounts of drugs held in a country or territory for domestic consumption, manufacture of other drugs, or export;

*(g)* “Special stocks” means the amounts of drugs held by the Government of a country or territory for special government purposes and to meet exceptional circumstances.

3. All drugs are included in the List of Narcotic Drugs under International Control (“Yellow List”), a supplement to the statistical forms on narcotic drugs, distributed to Governments on a yearly basis.

4. Figures included in this form should be expressed in terms of **the pure anhydrous drug content** contained in crude drugs, salts and preparations. Tables showing the pure drug content of bases and salts and the equivalent amounts of the pure drug of certain extracts and tinctures are given in the List of Narcotic Drugs under International Control (“Yellow List”).

5. **The estimated quantities should be expressed in kilograms and grams without decimal points or commas.**

***Part I*:This part is to be filled in by all Governments.**

6. Governments are required to provide information on some health-related parameters and on the method used to determine the estimates furnished in this Form B.

***Part II*:This part is to be filled in by all Governments.**

7. ***Column 1*:** The term **“quantity to be consumed”** refers to the quantity to be supplied for retail distribution, use in medical treatment or scientific research, to any person, enterprise or institute (retail pharmacists, other authorized retail distributors, institutions or qualified persons duly authorized to exercise therapeutic or scientific functions such as doctors, dentists, veterinarians, hospitals, dispensaries and similar health institutions, scientific institutes, both public and private). Only the amounts needed for *domestic* purposes and not those required for export should be taken into account.

8. ***Column 2*:** Not only the requirements for *domestic* purposes, but also those for *export* should be taken into account.

9. ***Column 2*** *(a)*: The estimated quantities should include the quantities of the **drug to be transformed by a chemical process into another drug, but not the amounts of the drug to be transformed into the salts thereof.** For example, the quantities of morphine base to be converted into codeine base, but not the quantities of morphine base to be transformed into morphine hydrochloride or morphine sulphate.

10. ***Column 2*** *(b)*: The estimated quantities in this column should include the quantities of drugs needed for the manufacture of **preparations for the export of which authorizations are not required (Schedule III preparations),** whether such preparations are intended for domestic consumption or for export. For example, quantities of codeine base to manufacture preparations containing codeine phosphate with a concentration of not more than 2.5 per cent (e.g. 3 mg/15 ml).

11. ***Column 2*** *(c)*: The estimated quantities to be inserted in this column should include the quantities **of** drugs needed for the manufacture of **substances not covered by the 1961 Convention,** for example, quantities of thebaine to manufacture naloxone and buprenorphine, and quantities of cannabis needed to manufacture cannabis-based substances, such as THC/Δ9-THC, Dronabinol, Sativex®, CBD, Epidiolex®, CBD isolate, CBN, CBDV and other cannabinoids.

12. ***Column 3*:** The term **“special stocks”** is defined in article 1, paragraph 1 (w), of the 1961 Convention as “the amounts of drugs held in a country or territory by the government of such country or territory for special Government purposes and to meet exceptional circumstances”. Quantities held for “special Government purposes” include in particular the requirements for the armed forces. “Exceptional circumstances” refers to catastrophic events such as large-scale epidemics and major earthquakes. The quantities to be added to the stocks held by the Government for the normal needs of the civilian population are not to be taken into account in computing the estimated quantities to be inserted in this column. The quantities to be held by the Government for such purposes should be included in the estimates to be inserted in column 4.

13. ***Column 4*:** Governments are required to furnish an estimate of the stocks they expect to hold at the end of the year. The quantities should cover the actual stocks held at 31 December of the year to which the estimates relate. The estimate should include the quantities to be held in stock for domestic consumption, manufacture of other drugs or preparations and exports. The term **“stocks”,** in accordance with article 1, paragraph 1 (x), of the 1961 Convention, refers to the amounts of drugs held in a country or territory except:

*(a)* The quantities held by retail pharmacists or other authorized retail distributors and by institutions or qualified persons in the duly authorized exercise of therapeutic or scientific functions (see 7 above);

*(b)* “Special stocks” held by the Government. Stocks held by the Government for the normal needs of the civilian population should be included in column 4 (see 12 above).

14. **With respect to concentrate of poppy straw, the gross weight of the material (expressed in kilograms) and the average content of anhydrous alkaloids (anhydrous morphine alkaloid (AMA), anhydrous codeine alkaloid (ACA), anhydrous thebaine alkaloid (ATA) and anhydrous oripavine alkaloid (AOA)) are to be reported, expressed as a percentage.**

***Part III*: This part concerns countries and territories where synthetic narcotic drugs are manufactured for medical and/or scientific purposes.**

15. For the purposes of preparing the estimates and ensuring uniform interpretation of the term “synthetic drugs”, the definition proposed in the Commentary on the Protocol Amending the Single Convention on Narcotic Drugs, 1961 should be followed. The definition is as follows: “synthetic drugs are all drugs appearing in Schedules I and II [of the 1961 Convention], except those at present *normally* obtained from the opium poppy (its opium or straw), the coca bush or the cannabis plant.”

16. The “synthetic drugs”, as defined in paragraph 15, are listed in the corresponding part of this Form B.

17. **Industrial establishments** that simply manufacture salts or preparations of “synthetic drugs” from “synthetic drugs” manufactured in other industrial establishments in the country or abroad should not be included in the estimate. In fact, only the quantities of “synthetic drugs” to be manufactured should be included in the estimates, i.e. not any quantities of **preparations** of “synthetic drugs” to be manufactured.

18. Quantities should be rounded to the nearest kilogram, without decimal point or comma. Where the quantities are less than one kilogram, they should be rounded to the nearest gram, specifying that the quantities are in grams.

***Part IV*: This part concerns Governments of countries and territories where the cultivation of the opium poppy is authorized for the purpose of opium production.**

19. Governments should indicate the geographical locations in which it is permitted or intended to permit opium production in the calendar year to which the estimates relate, regardless of whether the sowing takes place in that year or in the preceding year. All areas sown should be expressed in hectares (1 hectare is equal to 10,000 square metres). The estimated quantities of opium to be produced must also be indicated. The amount of opium should be expressed in kilograms and the average moisture content (as a percentage) should also be provided. All quantities should be rounded to the nearest kilogram, without decimal point or comma.

***Part V*: This part concerns Governments of countries and territories where the cultivation of the opium poppy is authorized for purposes other than opium production.**

20. The information furnished should include the geographical location of land used for the cultivation of opium poppy and the area estimated to be in use for the cultivation of opium poppy harvested during the calendar year to which the estimates relate, regardless of when the sowing takes place, in that year or in the preceding year. Geographical locations should be reported as precisely as possible, indicating state/province and county/municipality. Areas should be expressed in hectares (1 hectare is equal to 10,000 square metres).

21. **With respect to poppy straw to be produced for the manufacture of narcotic drugs, the estimated quantities of AMA (anhydrous morphine alkaloid), ACA (anhydrous codeine alkaloid), ATA (anhydrous thebaine alkaloid) and AOA (anhydrous oripavine alkaloid) to be obtained from the poppy straw are to be reported including alkaloids obtained from PS(N).**

***Part VI*: This part concerns Governments of countries and territories that authorize the cultivation of the cannabis plant for the production of cannabis for medical and/or scientific purposes.**

22. The information furnished should include the geographical location of land used for the cultivation of cannabis and the area estimated ( if applicable) to be in use for the cultivation of cannabis during the calendar year to which the estimates relate, regardless of whether the sowing takes place in that year or in the preceding year. Geographical locations should be reported as precisely as possible, indicating state/province and county/municipality. Areas should be expressed in hectares (1 hectare is equal to 10,000 square metres). Production of cannabis flowering top should be reported in kg of dry cannabis at 10 per cent moisture content.

***Part VII*: This part concerns Governments of countries and territories that authorize the cultivation of the coca bush for the production of coca leaf.**

23. The information furnished should include the geographical location of land used for the cultivation of coca bush and the area estimated to be in use for the cultivation of coca bush during the calendar year to which the estimates relate, regardless of when the sowing takes place, in that year or in the preceding year. Geographical locations should be reported as precisely as possible, indicating state/province and county/municipality. Areas should be expressed in hectares (1 hectare is equal to 10,000 square metres).

**Note:** Specific guidelines for completing this Form B, with detailed explanations and practical examples, can be found in part II, section II, of the training material on the estimates system for narcotic drugs, available on the INCB website: <https://www.incb.org/documents/Narcotic-Drugs/Training-Materials/English/PART_II_English.pdf>.

**Part I**

**Background information and statement of the method**

*Number of medical practitioners in the country or territory*:

Doctors: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Dentists: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Veterinarians: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Number of pharmacies:* \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Number of hospitals:* \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ *Total number of hospital beds:* \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**STATEMENT OF THE METHOD**

Please comment on the methods used in determining the various estimates reported in this form and on trends in the requirements for narcotic drugs

**ADDITIONAL INFORMATION**

Please provide any other information that may be useful to the Board  
in examining the estimated drug requirements

**Part II**

**Annual estimates of requirements for narcotic drugs  
(for all countries and territories)**

| Narcotic drug | 1 | | 2 | | | | | | 3 | | 4 | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Quantity to be consumed for domestic medical and scientific purposes | | Quantity to be utilized for the manufacture of: | | | | | | Quantity to be added to special stocks | | Quantity to be held in stocks at 31 December of the year to which the estimates relate | |
| *(a)* Other drugs covered under 1961 Convention | | *(b)* Preparations included in Schedule III of the 1961 Convention | | *(c)* Substances not covered by the 1961 Convention\* | |
| Regardless of whether these other drugs, preparations  or substances are intended for domestic consumption  or for export | | | | | |
| kg | g | kg | g | kg | g | kg | g | kg | g | kg | g |
| Alphaprodine |  |  |  |  |  |  |  |  |  |  |  |  |
| Anileridine |  |  |  |  |  |  |  |  |  |  |  |  |
| Bezitramide |  |  |  |  |  |  |  |  |  |  |  |  |
| Cannabis\*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| Cannabis resin |  |  |  |  |  |  |  |  |  |  |  |  |
| Coca leaf |  |  |  |  |  |  |  |  |  |  |  |  |
| Cocaine |  |  |  |  |  |  |  |  |  |  |  |  |
| Codeine |  |  |  |  |  |  |  |  |  |  |  |  |
| Dextromoramide |  |  |  |  |  |  |  |  |  |  |  |  |
| Dextropropoxyphene |  |  |  |  |  |  |  |  |  |  |  |  |
| Difenoxin |  |  |  |  |  |  |  |  |  |  |  |  |
| Dihydrocodeine |  |  |  |  |  |  |  |  |  |  |  |  |
| Diphenoxylate |  |  |  |  |  |  |  |  |  |  |  |  |
| Dipipanone |  |  |  |  |  |  |  |  |  |  |  |  |
| Ethylmorphine |  |  |  |  |  |  |  |  |  |  |  |  |
| Heroin |  |  |  |  |  |  |  |  |  |  |  |  |
| Hydrocodone |  |  |  |  |  |  |  |  |  |  |  |  |
| Hydromorphone |  |  |  |  |  |  |  |  |  |  |  |  |
| Ketobemidone |  |  |  |  |  |  |  |  |  |  |  |  |
| Levorphanol |  |  |  |  |  |  |  |  |  |  |  |  |
| Methadone |  |  |  |  |  |  |  |  |  |  |  |  |
| Morphine |  |  |  |  |  |  |  |  |  |  |  |  |
| Nicomorphine |  |  |  |  |  |  |  |  |  |  |  |  |
| Normethadone |  |  |  |  |  |  |  |  |  |  |  |  |

\*Including quantities of cannabisto manufacture THC/Δ9-THC, Dronabinol, Sativex®, CBD, Epidiolex®, CBD isolate, CBN, CBDV and other cannabinoids from cannabis plant

\*\*Quantities of the cannabis flowering top to be expressed in gross weight (GW) at 10 per cent moisture content.

**Part II**

**Annual estimates of requirements for narcotic drugs  
(for all countries and territories)**

| Narcotic drug | 1 | | 2 | | | | | | 3 | | 4 | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Quantity to be consumed for domestic medical and scientific purposes | | Quantity to be utilized for the manufacture of: | | | | | | Quantity to be added to special stocks | | Quantity to be held in stocks at 31 December of the year to which the estimates relate | |
| *(a)* Other drugs | | *(b)* Preparations included in Schedule III of the 1961 Convention | | *(c)* Substances not covered by the 1961 Convention | |
| Regardless of whether these other drugs, preparations  or substances are intended for domestic consumption  or for export | | | | | |
| kg | g | kg | g | kg | g | kg | g | kg | g | kg | g |
| Opium |  |  |  |  |  |  |  |  |  |  |  |  |
| Oripavine |  |  |  |  |  |  |  |  |  |  |  |  |
| Oxycodone |  |  |  |  |  |  |  |  |  |  |  |  |
| Oxymorphone |  |  |  |  |  |  |  |  |  |  |  |  |
| Pethidine |  |  |  |  |  |  |  |  |  |  |  |  |
| Phenoperidine |  |  |  |  |  |  |  |  |  |  |  |  |
| Pholcodine |  |  |  |  |  |  |  |  |  |  |  |  |
| Thebacon |  |  |  |  |  |  |  |  |  |  |  |  |
| Thebaine |  |  |  |  |  |  |  |  |  |  |  |  |
| Tilidine |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | g | mg | g | mg | g | mg | g | mg | g | mg | g | mg |
| Fentanyl |  |  |  |  |  |  |  |  |  |  |  |  |
| Alfentanil |  |  |  |  |  |  |  |  |  |  |  |  |
| Remifentanil |  |  |  |  |  |  |  |  |  |  |  |  |
| Sufentanil |  |  |  |  |  |  |  |  |  |  |  |  |
| Etorphine |  |  |  |  |  |  |  |  |  |  |  |  |
| Piritramide |  |  |  |  |  |  |  |  |  |  |  |  |

**Part II**

**Annual estimates of requirements for narcotic drugs**

**(for all countries and territories)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | Quantity to be consumed for domestic medical and scientific purposes | | Quantity to be utilized for the manufacture of: | | | | | | Quantity to be added to special stocks | | Quantity to be held in stocks at 31 December of the year to which the estimates relate | |
| *(a)* Other drugs | | *(b)* Preparations included in Schedule III of the 1961 Convention | | *(c)* Substances not covered by the 1961 Convention | |
| Regardless of whether these other drugs, preparations or substances are intended  for domestic consumption or for export | | | | | |
|  | Alkaloid content in % | kg | g | kg | g |  |  | kg | g | kg | g | kg | g |
| Concentrate of poppy straw (M) | | \* |  | \* |  |  |  | \* |  | \* |  | \* |  |
| AMA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| ACA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| ATA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| AOA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| Concentrate of poppy straw (T) | | \* |  | \* |  |  |  | \* |  | \* |  | \* |  |
| ATA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| AMA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| AOA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| ACA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| Concentrate of poppy straw (O) | | \* |  | \* |  |  |  | \* |  | \* |  | \* |  |
| AOA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| AMA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| ATA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| ACA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| Concentrate of poppy straw (C) | | \* |  | \* |  |  |  | \* |  | \* |  | \* |  |
| ACA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| AMA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| ATA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |
| AOA | % \*\* |  |  |  |  |  |  |  |  |  |  |  |  |

\* Quantities to be expressed in gross weight.

\*\* Average anhydrous alkaloid content of the concentrate of poppy straw.

# Part III

**Annual estimates for the manufacture of synthetic narcotic drugs**

**(concerns only countries and territories where the manufacture of synthetic narcotic drugs is authorized)**

**A. Synthetic narcotic drugs in Schedule I of the 1961 Convention**

Acetylmethadol

Acetyl-*alpha*-methylfentanyl

*alpha*-Methylfentanyl

*alpha*-Methylthiofentanyl

Alfentanil

Allylprodine

Alphacetylmethadol

Alphameprodine

Alphamethadol

Alphaprodine

Anileridine

Benzethidine

Betacetylmethadol

*beta*-Hydroxyfentanyl

*beta*-Hydroxy-3-methyl fentanyl

Betameprodine

Betamethadol

Betaprodine

Bezitramide

Clonitazene

Dextromoramide

Diampromide

Diethylthiambutene

Difenoxin

Dimenoxadol

Dimepheptanol

Dimethylthiambutene

Dioxaphetyl butyrate

Diphenoxylate

Dipipanone

Drotebanol

Ethylmethylthiambutene

Etonitazene

Etoxeridine

Fentanyl

Furethidine

Hydroxypethidine

Isomethadone

Ketobemidone

Levomethorphan

Levomoramide

Levophenacylmorphan

Levorphanol

Metazocine

Methadone

Methadone intermediate

3-Methylfentanyl

3-Methylthiofentanyl

Moramide intermediate

Morpheridine

MPPP

Noracymethadol

Norlevorphanol

Normethadone

Norpipanone

PEPAP

Pethidine

Pethidine intermediate A

Pethidine intermediate B

Pethidine intermediate C

Phenadoxone

Phenampromide

Phenazocine

Phenomorphan

Phenoperidine

Piminodine

Piritramide

Proheptazine

Properidine

Racemethorphan

Racemoramide

Racemorphan

Remifentanil

Sufentanil

Thiofentanyl

Tilidine

Trimeperidine

**B. Synthetic narcotic drugs in Schedule II of the 1961 Convention**

Dextropropoxyphene

Propiram

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Industrial establishments that will be engaged in the manufacture of  synthetic drugs** | Quantities of synthetic drugs to be manufactured by each industrial establishment (In kilograms) | | | | | | | | |
| **Dextropro­poxyphene** | **Diphenoxylate** | **Fentanyl** | **Methadone** | **Pethidine** | **Tilidine** |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |

**Part IV**

**Annual estimate of the cultivation of the opium poppy for opium production**

**(concerns only Governments of countries and territories where the cultivation of the opium poppy is   
authorized for the purpose of opium production)**

|  |  |  |  |
| --- | --- | --- | --- |
| I | II | III | |
| **Geographical location of land used for the cultivation of the opium poppy** | **Area used for poppy cultivation  for the purpose of opium production (please indicate the area for each geographical location)** | **Quantity of opium to be produced** | |
| Hectares | Kilograms | Average moisture content in % |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Part V**

**Annual estimates of the cultivation of the opium poppy for  
purposes other than opium production**

**(concerns only Governments of countries and territories where the cultivation of the opium poppy is   
authorized for purposes other than the production of opium)**

|  |  |  |  |
| --- | --- | --- | --- |
| I | II | III\* | |
| **Geographical location of land used for the cultivation  of the opium poppy** | **Area (in hectares) used for poppy cultivation (please indicate the area for each geographical location)** | **Total estimated quantities of alkaloids to be obtained in the country** | |
| **A. For the purpose of producing poppy straw for the manufacture of narcotic drugs** | | | |
| 1. For poppy straw (M) |  | PS (M) | |
|  |  | Total PS (M) AMA (kg) |  |
|  |  | Total PS (M) ACA (kg) |  |
|  |  | Total PS (M) ATA (kg) |  |
|  |  | Total PS (M) AOA (kg) |  |
| 2. For poppy straw (T) |  | PS (T) | |
|  |  | Total PS (T) ATA (kg) |  |
|  |  | Total PS (T) AMA (kg) |  |
|  |  | Total PS (T) ACA (kg) |  |
|  |  | Total PS (T) AOA (kg) |  |
| 3. For poppy straw (O) |  | PS (O) | |
|  |  | Total PS (O) AOA  (kg) |  |
|  |  | Total PS (O) AMA  (kg) |  |
|  |  | Total PS (O) ATA  (kg) |  |
|  |  | Total PS (O) ACA  (kg) |  |

|  |  |  |  |
| --- | --- | --- | --- |
| 4. For poppy straw (C) | | PS (C) | |
|  |  | Total PS (C) ACA (kg) |  |
|  |  | Total PS (C) AMA (kg) |  |
|  |  | Total PS (C) ATA (kg) |  |
|  |  | Total PS (C) AOA (kg) |  |
| 5.. For poppy straw (N) | | PS(N) | |
|  | | Total PS (N) AMA (kg) |  |
|  | | Total PS (N) ACA (kg) |  |
|  | | Total PS (N) ATA (kg) |  |
|  | | Total PS (N) AOA (kg) |  |
| **B.** **For purposes other than producing opium or poppy straw for the manufacture of narcotic drugs** | | | |
|  |  |  | |
|  |  |  | |
|  |  |  | |
|  |  |  | |
|  |  |  | |
|  |  |  | |

\*Reported on a voluntary basis.

**Part VI**

**Annual estimates of cannabis production**

**(for Governments of countries and territories where the cultivation of the cannabis plant is   
authorized for the production of cannabis for medical and/or scientific purposes)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | I | II | III |
| **Cultivation of the cannabis plant** | **Geographical location of land used** | **Area used for the cultivation of the cannabis plant\*** | **Total estimated quantity of cannabis\*to be obtained in the country** |
| Hectares | Kilograms |
| 1. **For the production of cannabis for medical purposes** |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
| 2. **For the production of cannabis for scientific purposes** |  |  |  |
|  |  |  |  |
|  |  |  |  |

**\***If applicable.

**\*\***Quantity of the cannabis flowering top to be expressed in gross weight (GW) at 10 per cent moisture content.

**Part VII**

**Annual estimates of coca production**

**(for Governments of countries and territories where the cultivation of coca bush is authorized   
for the production of coca leaves)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Cultivation of the coca bush** | 1 | 2 | 3 |
| **Geographical location of land used** | **Area used for the cultivation of the coca bush** | **Total estimated  quantity to be obtained in the country** |
| Hectares | Kilograms |
| 1. **For the production of** **coca leaves**for the manufacture of cocaine and flavouring agents |  |  |  |
| **2. For the production of coca leaves** for the production of flavouring agents only |  |  |  |
| 3. **For the production of** **coca leaves** for purposes other than those listed in 1 and 2. |  |  |  |